Status:
TERMINATED
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Lead Sponsor:
Pharmacyclics LLC.
Conditions:
Leukemia
Leukemia, Lymphocytic, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or...
Eligibility Criteria
Inclusion
- At least 18 years old
- Refractory or relapsed CLL
- ECOG performance status score of 0, 1, or 2
- Each patient must sign a study-specific informed consent form
Exclusion
- Laboratory values of:
- Platelet count \<30,000/uL
- AST or ALT \>2 x the upper limit of normal (ULN)
- Total bilirubin \>2 x ULN
- Creatinine \>2.0 mg/dL
- Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment
- Women who are pregnant or lactating
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00076401
Last Update
June 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Medical Center
Columbus, Ohio, United States